Patrick Harrison, Kristina Nordlander, Sep 30, 2010
Five years and two weeks is a long time to wait for a judgment on appeal. For many, it is too long. However, such is the nature of the General Court’s July 1, 2010 judgment in AstraZeneca v Commission that innovative pharmaceutical manufacturers and other companies who are at risk of being found dominant may well wish the Court had never issued its judgment at all. Although the precise implications of the AstraZeneca judgment for the Eur
THIS ARTICLE IS NOT AVAILABLE FOR IP ADDRESS 3.140.185.147
Please verify email or join us to access premium content!